MAXIMUS (MMS) Upgraded by Zacks Investment Research to “Buy”

MAXIMUS (NYSE:MMS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage presently has a $71.00 target price on the health services provider’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 6.16% from the company’s previous close.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

Several other equities research analysts have also commented on MMS. Canaccord Genuity decreased their price objective on shares of MAXIMUS from $62.00 to $61.00 and set a “hold” rating on the stock in a research report on Friday, November 10th. Maxim Group reiterated a “hold” rating and issued a $69.00 price objective (up from $66.00) on shares of MAXIMUS in a research report on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. MAXIMUS presently has an average rating of “Hold” and a consensus price target of $66.60.

MAXIMUS (NYSE:MMS) opened at $66.88 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.57 and a current ratio of 2.57. MAXIMUS has a 12 month low of $57.12 and a 12 month high of $72.71. The firm has a market cap of $4,261.69, a price-to-earnings ratio of 20.55, a PEG ratio of 2.17 and a beta of 1.21.

MAXIMUS (NYSE:MMS) last posted its quarterly earnings results on Thursday, February 8th. The health services provider reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.01. MAXIMUS had a net margin of 8.99% and a return on equity of 22.93%. The business had revenue of $623.10 million for the quarter, compared to analysts’ expectations of $624.36 million. During the same period in the prior year, the company posted $0.71 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. research analysts predict that MAXIMUS will post 3.44 earnings per share for the current year.

In other MAXIMUS news, General Counsel David Francis sold 1,373 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $65.35, for a total value of $89,725.55. Following the transaction, the general counsel now directly owns 13,617 shares in the company, valued at approximately $889,870.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Richard A. Montoni sold 30,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $69.25, for a total transaction of $2,077,500.00. The disclosure for this sale can be found here. Insiders sold a total of 69,617 shares of company stock worth $4,789,052 over the last quarter. Insiders own 3.10% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio lifted its holdings in MAXIMUS by 0.3% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 73,252 shares of the health services provider’s stock valued at $4,588,000 after purchasing an additional 207 shares in the last quarter. Stifel Financial Corp lifted its holdings in MAXIMUS by 5.2% in the 2nd quarter. Stifel Financial Corp now owns 9,186 shares of the health services provider’s stock valued at $576,000 after purchasing an additional 455 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in MAXIMUS by 16.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,969 shares of the health services provider’s stock valued at $249,000 after purchasing an additional 546 shares in the last quarter. Eqis Capital Management Inc. lifted its holdings in MAXIMUS by 13.7% in the 3rd quarter. Eqis Capital Management Inc. now owns 6,663 shares of the health services provider’s stock valued at $430,000 after purchasing an additional 804 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in MAXIMUS by 0.5% in the 4th quarter. American International Group Inc. now owns 176,692 shares of the health services provider’s stock valued at $12,648,000 after purchasing an additional 907 shares in the last quarter. Institutional investors own 95.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “MAXIMUS (MMS) Upgraded by Zacks Investment Research to “Buy”” was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2018/02/15/maximus-mms-upgraded-by-zacks-investment-research-to-buy.html.

MAXIMUS Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on MAXIMUS (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply